Body Handbook კატალოგი პროფილი რეიტინგი
სკრინინგი BODY HANDBOOK
სკრინინგი · §142
Skin Cancer Screening
The same melanoma is a punch biopsy and a quiet afternoon at two millimetres, or a year of immunotherapy and a coin-flip at four. Survival is set almost entirely by how thick the spot was the day it came off, not by the drug that follows SEER 2024. So the highest-leverage cancer screen you own is free: five minutes a month in a mirror, catching the thing while it's still thin. A dermatologist earns a slot only if you carry real risk.
Screen · ყოველწლიურად მტკიცებულება განვითარებადი თავი სკრინინგი

Melanoma is the rare cancer where survival is basically one number: how deep the lesion had gone the day it came off. Confined to the skin, five-year survival is around 99%; once it reaches distant organs, about 35% 1. Every drug and surgical trick is small next to finding it a year earlier. Screening isn't treatment; it buys the window where a scalpel and local anesthetic still end it.

The honest gap: no trial has proven that screening everyone saves lives, which is why US primary-care guidance rates it "insufficient evidence" for average-risk adults 2. The observational data leans one way. One German region gave every adult a free whole-body exam; melanoma deaths fell by about half over five years, though critics argued it reversed once the program ended 3, 4. Regular self-examiners died at roughly a third the rate of non-examiners 5. The mechanism is settled; only the population math stays argued.

Learn your own skin so a new spot jumps out. Two lenses. ABCDE: asymmetry, uneven border, more than one colour, diameter over a pencil eraser, and evolving, the one that matters most; anything new, growing, itching, or bleeding gets looked at even if it scores zero on the rest 6, 7. And the ugly duckling: the spot unlike your others 8.

Self-exam is for everyone; a yearly dermatologist is for high risk. The lists converge 9, 10, 11: a prior skin cancer (a second is 5–10x likelier), a first-degree relative with melanoma, over 100 moles or 5-plus atypical ones, very fair skin that always burned, or long-term immunosuppression. One item earns an annual exam; two or three, every six months. No items, self-exam alone.

Most months, nothing happens, which is the point. The payoff compresses into the one visit where a spot fails the check: a punch biopsy, a small excision, a scar, done, no scans or immunotherapy behind it. The version where nobody looked is where that same lesion returns years later as a thick, spreading melanoma an order of magnitude harder to treat.

The fine print — when to skip it, and what people get wrong

"It would itch or bleed first." Most early melanomas are silent; that's why you look. "Only sun-exposed skin." Melanoma also grows on soles, palms, under nails, and genitals, often the main site in darker skin. "Everyone needs an annual check." Not for average risk 2.

Overdiagnosis: in-situ melanoma is diagnosed far more than in 1975 while deaths stay flat, one estimate putting the overdiagnosed fraction near 60% in White US patients 12, 13. Nodular melanoma: grows deep, looks tidy under ABCDE; a firm bump bigger than last month is its own emergency.

References
  1. 1SEER (2024). Cancer Stat Facts: Melanoma of the Skin. link
  2. 2USPSTF (2023). Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. link
  3. 3Katalinic A, Waldmann A, Weinstock MA, et al. (2012). Does skin cancer screening save lives? An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. link
  4. 4Stang A, Jöckel KH (2016). Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany. Cancer. link
  5. 5Berwick M, Begg CB, Fine JA, et al. (1996). Screening for cutaneous melanoma by skin self-examination. Journal of the National Cancer Institute. link
  6. 6Friedman RJ, Rigel DS, Kopf AW (1985). Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA: A Cancer Journal for Clinicians. link
  7. 7Abbasi NR, Shaw HM, Rigel DS, et al. (2004). Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. link
  8. 8Grob JJ, Bonerandi JJ (1998). The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Archives of Dermatology. link
  9. 9Watts CG, Dieng M, Morton RL, et al. (2015). Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. British Journal of Dermatology. link
  10. 10Garbe C, Amaral T, Peris K, et al. (2022). European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. European Journal of Cancer. link
  11. 11Gandini S, Sera F, Cattaruzza MS, et al. (2005). Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. European Journal of Cancer. link
  12. 12Welch HG, Mazer BL, Adamson AS (2021). The rapid rise in cutaneous melanoma diagnoses. New England Journal of Medicine. link
  13. 13Adamson AS, Suarez EA, Welch HG (2022). Estimating overdiagnosis of melanoma using trends among Black and White patients in the US. JAMA Dermatology. link
·
142